Arca
Skip to content
Tools
Tools

Label Changes: Empaveli (pegcetacoplan)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Empaveli label DailyMed has published, from Apellis Pharmaceuticals, Inc., and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 13
  • Sections changed, version 13 to 14: 7

What changed from version 13 to version 14

Aug 4, 2025 to Aug 25, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Indications and usageChanged · 16 words added, 10 removed
  2. Adverse reactionsChanged · 54 words added, 24 removed
  3. Use in specific populationsChanged · 1 word added
  4. Clinical pharmacologyChanged · 47 words added, 11 removed
  5. Clinical studiesChanged · 89 words added, 36 removed
  6. Medication guideChanged · 11 words added, 5 removed
  7. Untitled sectionChanged · 6 words added, 6 removed

Indications and usage

Changed16 words added, 10 removed
2 unchanged lines
EMPAVELI® is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
1.2 C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis
1.2 C3 Glomerulopathy or Primary Immune-Complex Membranoproliferative Glomerulonephritis
EMPAVELI® is indicated for the treatment of adult and pediatric patients aged 12 years and older with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN), to reduce proteinuria and the loss of kidney function.

Adverse reactions

Changed54 words added, 24 removed
76 unchanged lines
C3 Glomerulopathy or Primary IC-MPGN
Study in Adult and Pediatric Patients 12 Years of ageAge and olderOlder with C3G or primaryPrimary IC-MPGN (Study APL2-C3G-310)
The data described below reflects the exposure in adult (n=35) and pediatric patients 12 years of age and older (n=28) with native kidney C3G (n=46), native kidney primary IC-MPGN (n=12), or recurrent C3G following kidney transplant (n=5) who received EMPAVELI at the recommended dosing regimens during the 26-week placebo-controlled period of Study APL2-C3G-310. Serious adverse reactions due to viral infections resulting in hospitalizations occurred in 2 (3%) patients with C3G or primary IC-MPGN receiving EMPAVELI and 1 (2%) patient on placebo. One patient (2%) on EMPAVELI with native kidney C3G died because of respiratory failure due to COVID-19 pneumonia; there were no deaths in the placebo arm.
Table 4 describes the adverse reactions that were reported in ≥5% of patients (adults and pediatric patients 12 years of age and older) treated with EMPAVELI and at a greater incidence than placebo in Study APL2-C3G-310. Adverse reactions in pediatric patients were similar to those seen in adults.
TheFollowing the 26-week placebo-controlled period ofin Study APL2-C3G-310, was118 followedpatients bywere treated with EMPAVELI at the recommended dosing regimen for a 26-week open-label period. The safety profile was consistent with that observed during the 26-week placebo-controlled period. During the open-label period, one patient with native kidney C3G had a serious adverse event of pneumonia secondary to Streptococcus pneumoniae, and one patient with recurrent C3G following kidney transplant developed herpes zoster meningoencephalitis while on concomitant immunosuppression, leading to treatment discontinuation.
Table 4: Adverse Reactions Reported in ≥5% of Patients (adult and pediatric) Treated with EMPAVELI and Greater than Placebo in Study APL2-C3G-310
11 unchanged lines
Cough | 6 (10) | 1 (2)
Study in Adult recurrent C3G or primary IC-MPGN following kidney transplant (Study APL2-C3G-204)
Study in Adult Recurrent C3G or Primary IC-MPGN Following Kidney Transplant (Study APL2-C3G-204)
In a study in 13 adults with recurrent C3G or primary IC-MPGN after kidney transplant (NCT#04572854), one patient with primary IC-MPGN experienced a serious adverse event of Pneumocystis jirovecii pneumonia while on EMPAVELI and concurrent immunosuppressive medications.
3 unchanged lines

Use in specific populations

Changed1 word added
22 unchanged lines
8.4 Pediatric Use
The safety and effectiveness of EMPAVELI for the treatment of C3G or primary IC-MPGN have been established in pediatric patients aged 12 years and older. Use of EMPAVELI for this indication is supported by evidence from an adequate and well controlled trial that enrolled 55 pediatric patients aged 12 years and older [see Adverse Reactions (6.1), and Clinical Studies (14.2)]. The safety and effectiveness of EMPAVELI in pediatric patients less than 12 years of age with C3G or primary IC-MPGN have not been established.
Safety and effectiveness of EMPAVELI in pediatric patients with PNH have not been established.
2 unchanged lines

Clinical pharmacology

Changed47 words added, 11 removed
3 unchanged lines
In PNH, extravascular hemolysis (EVH) is facilitated by C3b opsonization while intravascular hemolysis (IVH) is mediated by the downstream membrane attack complex (MAC). Pegcetacoplan acts proximally in the complement cascade controlling both C3b-mediated EVH and terminal complement-mediated IVH.
In C3G and primary IC-MPGN, complement dysregulation and overactivation causes deposition of C3 fragments in glomeruli, which contributes to the pathogenesis of C3G and is thought to contribute to the pathogenesis of primary IC-MPGN. Pegcetacoplan binds C3 and its activation fragment C3b, therefore inhibiting C3 activation, decreasing C3 glomerular fragment deposition, and decreasing C5 convertase activity and subsequent assembly of C5b-9.
12.2 Pharmacodynamics
2 unchanged lines
The mean percentage of PNH Type II + III RBCs with C3 deposition decreased from 17.8% at baseline to 0.2% at Week 16 and sustained through Week 48 (Study APL2-302). In Study APL2-308, the mean percentage of PNH Type II + III RBCs with C3 deposition decreased from 2.85% at baseline to 0.09% at Week 26.
In patients with C3G or primary IC-MPGN administered pegcetacoplan SC infusion twice weekly, mean (SD) serum C3 levels increased from 62 (48) mg/dL at baseline to 371 (120) mg/dL at Week 26 compared to no change with placebo. These increases were sustained through Week 52. Mean (SD) plasma soluble C5b-9 levels decreased from 903 (698) ng/mL at baseline to 290 (249) ng/mL at Week 26 with EMPAVELI compared to no change with placebo. These decreases were sustained through Week 52. Of patients with evaluable kidney biopsies (n=69), 74% of patients on pegcetacoplan had a decrease in C3 complement staining by at least 2 orders of magnitude from baseline to Week 26 compared to 12% on placebo (Study APL2-C3G-310).
Cardiac Electrophysiology
2 unchanged lines
In patients with PNH, the serum pegcetacoplan concentrations achieved steady-state approximately 4 to 6 weeks following the first dose. The exposure of pegcetacoplan increased proportionally over a dose range from 45 to 1,440 mg (0.04 to 1.33 times the approved recommended dose). The mean (CV%) trough serum concentration observed at Week 16 was 706 (15.1%) mcg/mL and sustained through Week 48 (Study APL2-302). In Study APL2-308, mean (CV%) trough serum concentration was 744 (25.5%) mcg/mL at Week 26.
In patients with C3G or primary IC-MPGN, serum pegcetacoplan concentrations reached steady state approximately 4 to 8 weeks following twice weekly SC infusion. The mean (CV%) trough serum concentrations ranged between 716 (31%) and 766 (23%) mcg/mL from Week 4 to Week 26 and were maintained through Week 52 (Study APL2-C3G-310).
Absorption
16 unchanged lines
The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the study described below with the incidence of anti-drug antibodies in other studies.
During the 2652-week placebo-controlled period in Study APL2-C3G-310, 1436 of 62123 participants (2329%) with C3G or primary IC-MPGN randomizedexposed to pegcetacoplan developed anti–pegcetacoplan peptide antibodies. TwoEight of 6236 participants with anti–pegcetacoplan peptide antibodies (322%) developed anti–pegcetacoplan peptide neutralizing antibodies (Study APL2-C3G-310). There was no identified clinically significant effect of anti-drug antibodies on pharmacokinetics, pharmacodynamics, safety, or effectiveness of pegcetacoplan over the treatment duration of 2652 weeks.

Clinical studies

Changed89 words added, 36 removed
77 unchanged lines
14.2 C3 Glomerulopathy (C3G) or Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
The efficacy of EMPAVELI in reducing proteinuria in adult and pediatric patients aged 12 years and older with native kidney C3G, native kidney IC-MPGN, or recurrent C3G following kidney transplant was demonstrated in Study APL2-C3G-310. Safety and effectiveness of EMPVAELIEMPAVELI in patients with recurrent IC-MPGN following kidney transplant have not been established.
APL2-C3G-310 iswas a randomized, double-blind, placebo-controlled study that included 124 adult and pediatric patients aged 12 years and older and weighing at least 30 kg with biopsy-proven, native kidney or post-transplant recurrent C3G, or native kidney primary IC-MPGN, eGFR ≥30 mL/min/1.73 m2, proteinuria ≥1 g/day, and urine protein-to-creatinine ratio (UPCR) ≥1 g/g (NTC 05067127). For at least 12 weeks before randomization and throughout the 26-week placebo-controlled period, patients were required to be on stable and optimized doses of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and/or sodium-glucose cotransporter-2 (SGLT2) inhibitors. Immunosuppressant medication doses (e.g., steroids no higher than 20 mg daily, mycophenolate mofetil, tacrolimus) had to be stable for at least 12 weeks before randomization and throughout the 26-week placebo-controlled period.
Patients were randomized (1:1) to EMPAVELI or placebo, administered twice weekly as a subcutaneous (SC) infusion for 26 weeks. Randomization was stratified by post-transplant recurrence and by kidney biopsy obtained within 28 weeks of screening. Adults and pediatric patients weighing 50 kg or more received EMPAVELI 1,080 mg (20 mL) twice weekly. Pediatric patients weighing 35 kg to less than 50 kg received 648 mg (12 mL) for the first infusion and 810 mg (15 mL) for each infusion thereafter. Pediatric patients weighing 30 kg to less than 35 kg received EMPAVELI 540 mg (10 mL) for the first 2 infusions and 648 mg (12 mL) twice weekly thereafter. After 26 weeks, all patients were treated with EMPAVELI twice weekly during the 26-week open-label period of the study.
Patients were vaccinated against Streptococcus pneumoniae, Neisseria meningitidis types A, C, W, Y, and B, and Haemophilus influenzae type B (Hib) at least 14 days prior to randomization, unless documented evidence existed that participants received the recommended vaccinations or were non-responders to vaccination.
2 unchanged lines
The primary efficacy endpoint was the log-transformed ratio of UPCR (sampled from first morning urine collections) at Week 26 compared to baseline. At Week 26, the geometric mean UPCR ratio relative to baseline was 0.33 (95% CI: 0.25, 0.43) and 1.03 (95% CI: 0.91, 1.16) in the EMPAVELI and placebo groups, respectively, resulting in a 68% reduction in UPCR from baseline in the EMPAVELI group compared to placebo (p<0.0001). The treatment effect was consistent across all subgroups including disease type, age, transplant status (C3G), sex, race, baseline disease characteristics (eGFR and UPCR), and immunosuppressant use.
Figure 2 shows the geometric mean UPCR ratio compared to baseline over time.
In patients initially randomized to EMPAVELI, the reduction in UPCR seen at 26 weeks was maintained at 52 weeks. In patients who switched from placebo to EMPAVELI, a reduction in UPCR was seen after switching to EMPAVELI at Week 26 (Figure 2).
Abbreviations: FMU = first-morning spot urine; UPCR = urine protein-to-creatinine ratio.
Figure 2: Geometric Mean of UPCR Ratio Compared to Baseline Over 2652 Weeks of Treatment - Study APL2-C3G-310
During the 26-week placebo-controlled period, 49% of patients in the EMPAVELI group achieved a compositekidney renalcomposite endpoint defined as a ≥50% reduction in UPCR and stable eGFR (≤15% reduction from baseline) compared with 3% of patients in the placebo group (odds ratio [95% CI] of 27 [6, 124], p<0.0001). Sixty percent of patients in the EMPAVELI group achieved a 50% or greater reduction in UPCR from baseline to Week 26 compared with 5% in the placebo arm, and 68% of patients in the EMPAVELI group had a stable eGFR (≤15% reduction from baseline to Week 26) compared with 59% in the placebo group. Over the first 6 months of treatment, EMPAVELI reduced the loss of kidney function compared to placebo (Figure 3). TheDuring efficacythe of6-month EMPAVELIopen-label inperiod, pediatricEMPAVELI patientsreduced 12the yearsloss of agekidney andfunction olderin waspatients similarinitially randomized to adultsplacebo (Figure 3).
Abbreviations: LS = least square
LS Mean (95% CI) of difference between EMPAVELI and placebo at Week 26 is 6.31 (0.50, 12.12) mL/min/1.73m2.
Figure 3: LS Mean of eGFR Compared to Baseline Over 2652 Weeks of Treatment - Study APL2-C3G-310

Medication guide

Changed11 words added, 5 removed
This Medication Guide has been approved by the U.S. Food and Drug Administration. | Revised: 78/20252026
MEDICATION GUIDE EMPAVELI® (em-puh-vel-ee) (pegcetacoplan) injection, for subcutaneous use
2 unchanged lines
Your healthcare provider will give you a Patient Safety Card about the risk of serious infections. Carry it with you at all times during treatment and for 2 months after your last dose of EMPAVELI. Your risk of serious infections may continue for several weeks after your last dose of EMPAVELI. It is important to show this card to any healthcare provider who treats you. This will help them diagnose and treat you quickly. EMPAVELI is only available through a program called the EMPAVELI Risk Evaluation and Mitigation Strategy (REMS). Before you can take EMPAVELI, your healthcare provider must: enroll in the EMPAVELI REMS program counsel you about the risk of serious infections caused by certain bacteria give you information about the symptoms of serious infections make sure that you are vaccinated against serious infections caused by encapsulated bacteria and that you receive antibiotics if you need to start EMPAVELI right away and you are not up to date on your vaccines give you a Patient Safety Card about your risk of serious infections, as discussed above For more information about side effects, see "What are the possible side effects of EMPAVELI?"
What is EMPAVELI? EMPAVELI is a prescription medicine used to: treat adults with a disease called paroxysmal nocturnal hemoglobinuria (PNH). treat adults and children 12 years of age and older with a kidney disease called complement 3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN), to reduce levels of protein in the urine (proteinuria) and the loss of kidney function. It is not known if EMPAVELI is safe and effective in children with PNH. It is not known if EMPAVELI is safe and effective in children under 12 years of age with C3G or primary IC-MPGN.
Do not take EMPAVELI if you: are allergic to pegcetacoplan or any of the ingredients in EMPAVELI. See the end of this Medication Guide for a complete list of ingredients in EMPAVELI. have a serious infection caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria meningitidis, or Haemophilus influenzae type B when you are starting EMPAVELI treatment.
12 unchanged lines
General information about the safe and effective use of EMPAVELI. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use EMPAVELI for a condition for which it was not prescribed. Do not give EMPAVELI to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about EMPAVELI that is written for health professionals.
What are the ingredients in EMPAVELI? Active ingredient: pegcetacoplan Inactive ingredients: sorbitol, glacial acetic acid, sodium acetate trihydrate, Water for Injection USP. EMPAVELI may also contain sodium hydroxide and/or additional glacial acetic acid for pH adjustment. Manufactured for: Apellis Pharmaceuticals, Inc. 100 Fifth Avenue Waltham, MA 02451 For patent information: www.apellis.com/productpatent Copyright © 20252026 Apellis Pharmaceuticals, Inc. All rights reserved. EMPAVELI is a registered trademark of Apellis Pharmaceuticals, Inc. For more information, go to www.EMPAVELI.com or call 1-866-692-7527. EMP-MG-28Jul202520Aug2026-78.0

Untitled section

Changed6 words added, 6 removed
1 unchanged line
For patent information: www.apellis.com/productpatent
Copyright © 20252026 Apellis Pharmaceuticals, Inc. All rights reserved.
EMPAVELI is a registered trademark of Apellis Pharmaceuticals, Inc.
EMP-PI-28Jul2025-7.0
EMP-PI-20Aug2026-8.0

Unchanged: Boxed warning, Dosage and administration, Dosage forms and strengths, Contraindications, Warnings and precautions, Description, Nonclinical toxicology, How supplied, Patient counseling information, Instructions for use, PRINCIPAL DISPLAY PANEL - 1,080 mg/20 mL Vial Carton, PRINCIPAL DISPLAY PANEL - 20 mL Injector Carton.

Every version

13 versions of set c23d89e9-b00b-4520-e053-2995a90a95af, newest first.
VersionPublished on DailyMedCompareSPL file
14Aug 25, 2026Shown belowDownload .zip
13Aug 4, 2025With version 12Download .zip
12Jun 18, 2025With version 11Download .zip
11Jan 9, 2025With version 10Download .zip
10Jul 4, 2024With version 9Download .zip
9Feb 19, 2024With version 8Download .zip
8Oct 12, 2023With version 7Download .zip
7Apr 17, 2023With version 6Download .zip
6Feb 23, 2023With version 5Download .zip
5Aug 12, 2021With version 4Download .zip
4Jul 13, 2021With version 3Download .zip
3Jun 21, 2021With version 2Download .zip
2Jun 15, 2021First versionDownload .zip

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.